Jurassic Products: FDA Resurrects Withdrawn Drugs To Study Liver Injury
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency soliciting contractor to produce 37 drugs withdrawn because of liver injury; goal is developing better tools for evaluating compounds in the pipeline.
You may also be interested in...
FDA Liver Injury Conference Another Chance To Inform Guidance Changes
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.